Role of ABCB1 in mediating chemoresistance of triple-negative breast cancers
Authors:
Open Access
- 17 February 2021
- journal article
- review article
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 41 (2)
Abstract
Triple-negative breast cancer (TNBC) is a group of breast cancers which neither express hormonal receptors nor human epidermal growth factor receptor. Hence, there is a lack of currently known targeted therapies and the only available line of systemic treatment option is chemotherapy or more recently immune therapy. However, in patients with relapsed disease after adjuvant or neoadjuvant therapy, resistance to chemotherapeutic agents has often developed, which results in poor treatment response. Multidrug resistance (MDR) has emerged as an important mechanism by which TNBCs mediate drug resistance and occurs primarily due to overexpression of ATP-binding cassette (ABC) transporter proteins such as P-glycoprotein (Pgp). Pgp overexpression had been linked to poor outcome, reduced survival rates and chemoresistance in patients. The aim of this mini-review is to provide a topical overview of the recent studies and to generate further interest in this critical research area, with the aim to develop an effective and safe approach for overcoming Pgp-mediated chemoresistance in TNBC.Keywords
This publication has 88 references indexed in Scilit:
- Neoadjuvant Chemotherapy Induces Expression Levels of Breast Cancer Resistance Protein That Predict Disease-Free Survival in Breast CancerPLOS ONE, 2013
- Molecular Pathways: Regulation and Therapeutic Implications of Multidrug ResistanceClinical Cancer Research, 2012
- Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistanceDrug Resistance Updates, 2012
- Clonal evolution in cancerNature, 2012
- Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomesInternational Journal of Pharmaceutics, 2011
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJournal of Clinical Investigation, 2011
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugsProceedings of the National Academy of Sciences, 2008
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast CancerJournal of Clinical Oncology, 2008
- Clinical trials of p-glycoprotein reversal in solid tumoursEuropean Journal of Cancer, 1996
- Transmembrane Aromatic Amino Acid Distribution in P-glycoproteinJournal of Molecular Biology, 1994